

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

Abattis Biologix Corporation
Suite 310 - 885 Dunsmuir St.
Vancouver BC V6C 1N5

Phone: 778-908-6650 Fax: 604-538-6658

Item 2. Date of Material Change

January 25, 2012

Item 3. News Release

A News Release dated and issued January 25, 2012 at Vancouver, British Columbia, through Canada Stockwatch, Market News and SEDAR.

Item 4. Summary of Material Change

See news release, a copy of which is attached hereto.

Item 5. Full Description of Material Change

See news release, a copy of which is attached hereto.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

Mike Withrow, President & CEO
Telephone: 778-908-6650

Item 9. Date of Report

January 25, 2011



Abattis Terminates ZITEK Licensing Agreement

VANCOUVER, British Columbia (January 25, 2012)—Abattis Biologix Corporation (CNSX: FLU) (the "Company") announces that it has today terminated its prior agreement with the Hensley Group Inc. dated October 8, 2010 pursuant to which it had been granted the exclusive license to make, have made, use and sell the nutraceutical anti-viral nasal spray product code named ZITEK.

About Abattis Biologix Corporation

Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The company has identified targeted channels to market and license proprietary patent pending products throughout the world.

ON BEHALF OF THE COMPANY

"Yazan Al Homsy"

Yazan Al Homsy
Director

For information please contact:
Hamza Thindal Capital Corp.

P: 888.371.9098
F: 888.371.9099
E: info@htcapitalcorp.com
<http://htcapitalcorp.com>

Neither the CNSX Exchange nor its regulations services accepts responsibility
for the adequacy or accuracy of this release.